Insiders Selling TransMedics Group And 2 Other Stocks
The Nasdaq 100 closed higher by around 0.7% on Monday. Investors, meanwhile, focused on some notable insider trades.
February PDUFA Catalysts Biotech Investors Must Know: Sanofi’s Bleeding Disorder Drug, Regeneron’s Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.
Ominous Death Cross Forms On Royalty Pharma’s Chart
If history is any guide, there may be trouble ahead for shares of Royalty Pharma (NASDAQ:RPRX). A so-called…
Royalty Pharma Highlights Accomplishments And Provides Business Update; 2022 Net Cash Provided By Operating Activities Expected To Be ~$2.14B-$2.15B; 2022 Adjusted Cash Receipts Expected To Be ~$2.785B-$2.790B, Towards The Upper End Of Guidance Range
2022 Net cash provided by operating activities (GAAP) expected to be approximately $2,140 million to $2,150 million; 2022 Adjusted Cash Receipts(1) (non-GAAP) expected to be
Arrowhead Pharmaceuticals Announces $25M Milestone Payment From Amgen
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced a $25M milestone payment from Amgen (NASDAQ:AMGN). This milestone was triggered by the first subject enrolled in Amgen's Phase 3 trial of
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Theravance Outlines $250M Capital Return Program; To Repurchase GSK’s Entire Holdings
Theravance Biopharma Inc (NASDAQ:TBPH) is buying back over 9.6 million shares from GSK plc (NYSE:GSK) for roughly $94 million, according to an…
Warren Buffett’s Berkshire Takes Another Bite Of Apple, Boosts Energy Holdings, Cashes Out Of Verizon: What 13F Filing Reveals
Warren Buffett-owned Berkshire Hathaway, Inc.’s (NYSE: BRK-A) (NYSE: BRK-B) portfolio saw some noteworthy and a few other nominal changes in the second quarter, according to the company's 13F filing.